Evidence map›Paper›PMID 21912619›Full record

ArticlePloS one2011

Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses.

Nathaniel J Schuldt, Yasser A Aldhamen, Daniel M Appledorn, Sergey S Seregin, Youssef Kousa, Sarah Godbehere, Andrea Amalfitano

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathaniel J SchuldtGenetics Program, Michigan State University, East Lansing, Michigan, United States of America.
Yasser A Aldhamen
Daniel M Appledorn
Sergey S Seregin
Youssef Kousa
Sarah Godbehere
Andrea Amalfitano

Funding

RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPYP01CA078673 · NCI · DUKE UNIVERSITY · PI MORSE, MICHAEL A · 1999 to 2008
$13.2M
ER-Localized Aminopeptidases in Ankylosing SpondylitisR01AR056981 · NIAMS · MICHIGAN STATE UNIVERSITY · PI AMALFITANO, ANDREA NA · 2010 to 2014
$1.5M
NCI NIH HHS P01 CA078673NIAMS NIH HHS R01 AR056981
6 · The paper itself

Abstract

backgroundMalaria greatly impacts the health and wellbeing of over half of the world's population. Promising malaria vaccine candidates have attempted to induce adaptive immune responses to Circumsporozoite (CS) protein. Despite the inclusion of potent adjuvants, these vaccines have limited protective efficacy. Conventional recombinant adenovirus (rAd) based vaccines expressing CS protein can induce CS protein specific immune responses, but these are essentially equivalent to those generated after use of the CS protein subunit based vaccines. In this study we combined the use of rAds expressing CS protein along with rAds expressing novel innate immune response modulating proteins in an attempt to significantly improve the induction of CS protein specific cell mediated immune (CMI) responses. METHODS AND

findingsBALB/cJ mice were co-vaccinated with a rAd vectors expressing CS protein simultaneous with a rAd expressing either TLR agonist (rEA) or SLAM receptors adaptor protein (EAT-2). Paradoxically, expression of the TLR agonist uncovered a potent immunosuppressive activity inherent to the combined expression of the CS protein and rEA. Fortunately, use of the rAd vaccine expressing EAT-2 circumvented CS protein's suppressive activity, and generated a fivefold increase in the number of CS protein responsive, IFNγ secreting splenocytes, as well as increased the breadth of T cells responsive to peptides present in the CS protein. These improvements were positively correlated with the induction of a fourfold improvement in CS protein specific CTL functional activity in vivo.

conclusionOur results emphasize the need for caution when incorporating CS protein into malaria vaccine platforms expressing or containing other immunostimulatory compounds, as the immunological outcomes may be unanticipated and/or counter-productive. However, expressing the SLAM receptors derived signaling adaptor EAT-2 at the same time of vaccination with CS protein can overcome these concerns, as well as significantly improve the induction of malaria antigen specific adaptive immune responses in vivo.

Indexed as

Adaptor Proteins, Signal TransducingAdenoviridaeAnimalsAntibody SpecificityAntigen PresentationB-LymphocytesImmune ToleranceImmunity, CellularImmunity, InnateImmunologic FactorsMaleMiceMice, Inbred BALB CProtozoan ProteinsT-LymphocytesToll-Like ReceptorsAdaptor Proteins, Signal Transducingcircumsporozoite protein, ProtozoanImmunologic FactorsProtozoan ProteinsToll-Like ReceptorsVaccines

Identifiers

PMID21912619
PMCPMC3166157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.